2021
DOI: 10.1159/000516959
|View full text |Cite
|
Sign up to set email alerts
|

Pressurized Intraperitoneal Aerosol Chemotherapy-Related Clinical Trials in the Treatment of Peritoneal Metastases

Abstract: <b><i>Introduction:</i></b> Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a treatment option for patients with peritoneal metastases. We evaluated the current status of ongoing prospective clinical trials investigating PIPAC to provide an overview and predict trends in this field. <b><i>Methods:</i></b> All 367,494 records of clinical trials registered at ClinicalTrials.gov were searched for trials dealing with PIPAC. Active or unpublished trials we… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 60 publications
(59 reference statements)
0
1
0
Order By: Relevance
“…It is important to note that supplementing perioperative chemotherapy and surgery with CRS HIPEC allows for a 5-year overall survival of up to 27% in metastatic patients who would most likely have died earlier otherwise [ 5 , 26 , 27 , 75 , 81 , 82 , 83 , 84 ]. In addition, neoadjuvant PIPAC has been successfully assessed in many specialized centers [ 61 , 62 , 85 ] and it is currently investigated in a dedicated trial [ 86 ].…”
Section: Resultsmentioning
confidence: 99%
“…It is important to note that supplementing perioperative chemotherapy and surgery with CRS HIPEC allows for a 5-year overall survival of up to 27% in metastatic patients who would most likely have died earlier otherwise [ 5 , 26 , 27 , 75 , 81 , 82 , 83 , 84 ]. In addition, neoadjuvant PIPAC has been successfully assessed in many specialized centers [ 61 , 62 , 85 ] and it is currently investigated in a dedicated trial [ 86 ].…”
Section: Resultsmentioning
confidence: 99%